vs

Side-by-side financial comparison of Citizens Community Bancorp Inc. (CZWI) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Citizens Community Bancorp Inc. is the larger business by last-quarter revenue ($15.8M vs $12.5M, roughly 1.3× Avidity Biosciences, Inc.). Citizens Community Bancorp Inc. runs the higher net margin — 27.1% vs -1398.3%, a 1425.4% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 14.9%). Citizens Community Bancorp Inc. produced more free cash flow last quarter ($10.4M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 1.9%).

Glacier Bancorp, Inc. is a regional multi-bank holding company headquartered in Kalispell, Montana, United States. It is a successor corporation to the Delaware corporation originally incorporated in 1990. The company provides personal and commercial banking services from 221 locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, and, Nevada.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

CZWI vs RNA — Head-to-Head

Bigger by revenue
CZWI
CZWI
1.3× larger
CZWI
$15.8M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+419.2% gap
RNA
434.0%
14.9%
CZWI
Higher net margin
CZWI
CZWI
1425.4% more per $
CZWI
27.1%
-1398.3%
RNA
More free cash flow
CZWI
CZWI
$167.3M more FCF
CZWI
$10.4M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
1.9%
CZWI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CZWI
CZWI
RNA
RNA
Revenue
$15.8M
$12.5M
Net Profit
$4.3M
$-174.4M
Gross Margin
Operating Margin
31.0%
-1513.5%
Net Margin
27.1%
-1398.3%
Revenue YoY
14.9%
434.0%
Net Profit YoY
58.1%
-117.0%
EPS (diluted)
$0.44
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CZWI
CZWI
RNA
RNA
Q4 25
$15.8M
Q3 25
$16.2M
$12.5M
Q2 25
$16.1M
$3.8M
Q1 25
$14.2M
$1.6M
Q4 24
$13.7M
$3.0M
Q3 24
$14.2M
$2.3M
Q2 24
$13.5M
$2.0M
Q1 24
$15.2M
$3.5M
Net Profit
CZWI
CZWI
RNA
RNA
Q4 25
$4.3M
Q3 25
$3.7M
$-174.4M
Q2 25
$3.3M
$-157.3M
Q1 25
$3.2M
$-115.8M
Q4 24
$2.7M
$-102.3M
Q3 24
$3.3M
$-80.4M
Q2 24
$3.7M
$-70.8M
Q1 24
$4.1M
$-68.9M
Operating Margin
CZWI
CZWI
RNA
RNA
Q4 25
31.0%
Q3 25
27.9%
-1513.5%
Q2 25
25.1%
-4448.7%
Q1 25
28.0%
-8360.9%
Q4 24
24.5%
-4069.6%
Q3 24
29.5%
-4200.9%
Q2 24
35.0%
-4040.4%
Q1 24
34.2%
-2178.6%
Net Margin
CZWI
CZWI
RNA
RNA
Q4 25
27.1%
Q3 25
22.7%
-1398.3%
Q2 25
20.3%
-4089.3%
Q1 25
22.5%
-7360.0%
Q4 24
19.7%
-3439.5%
Q3 24
23.1%
-3441.7%
Q2 24
27.2%
-3461.8%
Q1 24
26.9%
-1943.4%
EPS (diluted)
CZWI
CZWI
RNA
RNA
Q4 25
$0.44
Q3 25
$0.37
$-1.27
Q2 25
$0.33
$-1.21
Q1 25
$0.32
$-0.90
Q4 24
$0.28
$-0.80
Q3 24
$0.32
$-0.65
Q2 24
$0.35
$-0.65
Q1 24
$0.39
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CZWI
CZWI
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$118.9M
$350.2M
Total DebtLower is stronger
$51.8M
Stockholders' EquityBook value
$187.9M
$1.9B
Total Assets
$1.8B
$2.1B
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CZWI
CZWI
RNA
RNA
Q4 25
$118.9M
Q3 25
$82.4M
$350.2M
Q2 25
$67.5M
$243.9M
Q1 25
$100.2M
$254.2M
Q4 24
$50.2M
$219.9M
Q3 24
$36.6M
$370.2M
Q2 24
$36.9M
$575.8M
Q1 24
$28.6M
$471.4M
Total Debt
CZWI
CZWI
RNA
RNA
Q4 25
$51.8M
Q3 25
Q2 25
Q1 25
Q4 24
$66.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CZWI
CZWI
RNA
RNA
Q4 25
$187.9M
Q3 25
$186.8M
$1.9B
Q2 25
$183.5M
$1.2B
Q1 25
$180.1M
$1.3B
Q4 24
$179.1M
$1.4B
Q3 24
$180.1M
$1.5B
Q2 24
$176.0M
$1.2B
Q1 24
$172.8M
$830.9M
Total Assets
CZWI
CZWI
RNA
RNA
Q4 25
$1.8B
Q3 25
$1.7B
$2.1B
Q2 25
$1.7B
$1.4B
Q1 25
$1.8B
$1.5B
Q4 24
$1.7B
$1.6B
Q3 24
$1.8B
$1.6B
Q2 24
$1.8B
$1.3B
Q1 24
$1.8B
$951.5M
Debt / Equity
CZWI
CZWI
RNA
RNA
Q4 25
0.28×
Q3 25
Q2 25
Q1 25
Q4 24
0.37×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CZWI
CZWI
RNA
RNA
Operating Cash FlowLast quarter
$11.7M
$-156.2M
Free Cash FlowOCF − Capex
$10.4M
$-156.9M
FCF MarginFCF / Revenue
65.9%
-1257.6%
Capex IntensityCapex / Revenue
8.3%
5.7%
Cash ConversionOCF / Net Profit
2.74×
TTM Free Cash FlowTrailing 4 quarters
$17.5M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CZWI
CZWI
RNA
RNA
Q4 25
$11.7M
Q3 25
$6.6M
$-156.2M
Q2 25
$-406.0K
$-199.7M
Q1 25
$1.6M
$-124.8M
Q4 24
$20.4M
$-99.9M
Q3 24
$3.5M
$-65.6M
Q2 24
$5.1M
$-65.0M
Q1 24
$9.1M
$-70.4M
Free Cash Flow
CZWI
CZWI
RNA
RNA
Q4 25
$10.4M
Q3 25
$6.2M
$-156.9M
Q2 25
$-632.0K
$-203.0M
Q1 25
$1.5M
$-128.6M
Q4 24
$19.5M
$-103.8M
Q3 24
$3.4M
$-67.3M
Q2 24
$4.8M
$-65.5M
Q1 24
$8.9M
$-71.3M
FCF Margin
CZWI
CZWI
RNA
RNA
Q4 25
65.9%
Q3 25
38.4%
-1257.6%
Q2 25
-3.9%
-5277.1%
Q1 25
10.7%
-8174.3%
Q4 24
142.2%
-3491.0%
Q3 24
23.8%
-2881.8%
Q2 24
35.7%
-3204.6%
Q1 24
58.9%
-2012.3%
Capex Intensity
CZWI
CZWI
RNA
RNA
Q4 25
8.3%
Q3 25
2.4%
5.7%
Q2 25
1.4%
86.9%
Q1 25
0.7%
238.6%
Q4 24
6.5%
131.7%
Q3 24
0.9%
72.9%
Q2 24
2.3%
26.0%
Q1 24
1.4%
25.8%
Cash Conversion
CZWI
CZWI
RNA
RNA
Q4 25
2.74×
Q3 25
1.80×
Q2 25
-0.12×
Q1 25
0.50×
Q4 24
7.55×
Q3 24
1.07×
Q2 24
1.39×
Q1 24
2.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons